{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:29Z","timestamp":1794270149176,"version":"4.9.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005261","name":"Centre Hospitalier R\u00e9gional Universitaire de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107970","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:41:20Z","timestamp":1786981280000},"page":"107970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Electronic-nomogram-guided micafungin dosing regimen in critically ill patients: A population pharmacokinetic study"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-9151","authenticated-orcid":false,"given":"Jean-Joseph","family":"Bendjilali-Sabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlem","family":"Gammoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Conseil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Cazaubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107970_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003281","article-title":"Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network","volume":"9","author":"Galmiche","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0002","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","volume":"23","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal drugs TDM: trends and update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0005","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s15010-023-02078-9","article-title":"Posaconazole exposure in critically ill ICU patients: a need for action","volume":"51","author":"K\u00f6nig","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0006","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/myc.13469","article-title":"Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis","volume":"65","author":"H\u00f6hl","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53093-6","article-title":"Pharmacokinetics of Micafungin in critically ill patients","volume":"9","author":"Gastine","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0009","doi-asserted-by":"crossref","first-page":"116557","DOI":"10.1016\/j.jpba.2024.116557","article-title":"Multiparametric LC-MS\/MS method for simultaneous determination of eleven antifungal drugs and metabolites in human plasma","volume":"253","author":"Bendjilali-Sabiani","year":"2025","journal-title":"J Pharma Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0011","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bcp.12451","article-title":"Covariate selection in pharmacometric analyses: a review of methods","volume":"79","author":"Hutmacher","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0015","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0016","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.4, E.Def 9.4 and E.Def 11.0 procedures, Version 6.0, https:\/\/www.eucast.org\/fungi-afst\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-table\/;2025 [accessed December 25, 2025]."},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0018","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-021-01062-6","article-title":"Caspofungin population pharmacokinetic analysis in plasma and peritoneal fluid in septic patients with intra-abdominal infections: a prospective cohort study","volume":"61","author":"Garbez","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107078","article-title":"The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: a systematic review","volume":"63","author":"Jendoubi","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0022","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0023","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1124\/dmd.110.033811","article-title":"In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent Micafungin in humans and rats","volume":"38","author":"Yanni","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1472-8206.2009.00785.x","article-title":"Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia","volume":"24","author":"Konishi","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02466-18","article-title":"Pharmacokinetics of Caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels","volume":"63","author":"Kurland","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0026","first-page":"218","article-title":"Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis","volume":"17","author":"Qin","year":"2019","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11095-020-02980-z","article-title":"Optimization of Micafungin dosage for Chinese patients with sepsis in the Intensive care unit based on a population pharmacokinetic-pharmacodynamic analysis","volume":"38","author":"Zhong","year":"2021","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0028","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0029","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","article-title":"Population pharmacokinetic model and pharmacokinetic target attainment of Micafungin in intensive care unit patients","volume":"56","author":"Martial","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical Practice Guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0033","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0034","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0035","first-page":"86","article-title":"The importance of a fast-track pharmacology for the proper management of antibiotic therapy in intensive care units","volume":"37","author":"Cattaneo","year":"2023","journal-title":"Klinick\u00e1 Farmakologie a Farmacie"},{"key":"10.1016\/j.ijantimicag.2026.107970_bib0036","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:38:36Z","timestamp":1794267516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926002578"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107970","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electronic-nomogram-guided micafungin dosing regimen in critically ill patients: A population pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107970"}}